Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
University of Alberta
$60,000.00
Overcoming inactivation of oncolytic reovirus by proteases in breast tumor microenvironments.
EF 2020-21
Résumé
BACKGROUND: Reovirus (T3wt) is in phase 3 clinical trials for treatment of breast and other cancers. My laboratory seeks to further adapt reovirus towards breast tumor cells and environments, with hopes to improve the potency of reovirus therapy. Using expired project grant funding from CRS, we discovered that breast tumor microenvironments are enriched in zinc-dependent metalloproteases (MP) that cleave the T3wt cell attachment protein s1 and reduce reovirus infectivity towards many BC cell types by 100-fold. Moreover, we introduced a T249I mutation in s1 to withstand inactivation by BC MPs, which lead to improved tumor regression and prolonged survival in a syngeneic ErbB2+ BC (TuBO) immunocompotent mouse model, relative to T3wt. Aim 1 will conduct a comprehensive pre-clinical study of BC MP-resistant reovirus relative to T3wt in two BC models: the TuBo syngeneic model and the aggressive human MDA-MB-231 orthotopic xenograft model. We will use large sample sizes to monitor for survival and tumor regression benefits, and also to monitor reovirus s1 cleavage and virus replication kinetics within the tumors. If BC MPs reproducibly restrict reovirus oncolysis, then BC MP-resistant reovirus will show higher tumor clearance and infectious virus relative to ReoWT in multiple BC models, and prove itself worthwhile of clinical testing. Aim 2. We observed reovirus-inactivation and s1-cleavage by extracellular extracts of three mouse BC tumor types and five BC human cell lines. Triple negative breast cancers (TNBCs) are hardest to treat, so in aim 2, we will establish the repertoire of TNBC models that inactivate reovirus through MPs in their microenvironment. Secretion of MPs will first be evaluated in 17 human TNBC cell lines, and then confirmed in mouse xenograft tumors for 3 of these models. We will also evaluate reovirus-inactivating MP levels in the E0771 and EMT6 syngeneic orthotopic mouse TNBC models. The findings will not only reveal the prevalence of MPs as barriers to reovirus oncolysis, but will enable future efficacy trials in a variation of aggressive, metastatic TNBC models with different mouse genetic backgrounds and tumor immunities. Aim 3 will create reovirus variants with highly divergent s1 proteins that resist BC MPs, retain utmost infectivity in breast cancer cells, and avoid antibody cross-neutralization. The T249I mutation in s1 brought benefits to oncolytic activity but also costs to virus fitness that if overcome, may further enhance oncolytic activity. We therefore plan to switch s1 of ReoWT with s1 proteins from diverse reoviruses with as little as 22% amino acid similarity and that can withstand proteolytic cleavage. Some of these recombinant viruses that withstand cleavage will also ideally retain high infectivity in BC cells. Moreover, s1 is the immunodominant protein during antibody neutralization. By replacing s1 of ReoWT with s1 from other reovirus serotypes that do not cross-neutralize, we will create antigenically-distinct versions of oncolytic reovirus. In future, these recombinants will create the first tools to test the extent of oncolytic impairment imposed by host neutralizing antibodies against subsequent injections of the same oncolytic virus. OVERALL SIGNIFICANCE: This proposed project will provide detailed understanding of the obstacle created by BC MPs to reovirus therapy of breast cancers, and best-strategies to overcome this obstacle to maximize therapeutic efficacy. Note that other oncolytic viruses, antibodies, and protein-based therapies are proteinaceous as well and could be vulnerable to proteolysis; our novel findings on proteolysis as an obstacle to therapeutic activity in BC might therefore extend to other proteinaceous therapies as well.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
453388
Name
Shmulevitz Maya
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Overcoming inactivation of oncolytic reovirus by proteases in breast tumor microenvironments.
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Immunotherapy; Oncolytic Viruses &Amp
Abstract
BACKGROUND: Reovirus (T3wt) is in phase 3 clinical trials for treatment of breast and other cancers. My laboratory seeks to further adapt reovirus towards breast tumor cells and environments, with hopes to improve the potency of reovirus therapy. Using expired project grant funding from CRS, we discovered that breast tumor microenvironments are enriched in zinc-dependent metalloproteases (MP) that cleave the T3wt cell attachment protein s1 and reduce reovirus infectivity towards many BC cell types by 100-fold. Moreover, we introduced a T249I mutation in s1 to withstand inactivation by BC MPs, which lead to improved tumor regression and prolonged survival in a syngeneic ErbB2+ BC (TuBO) immunocompotent mouse model, relative to T3wt. Aim 1 will conduct a comprehensive pre-clinical study of BC MP-resistant reovirus relative to T3wt in two BC models: the TuBo syngeneic model and the aggressive human MDA-MB-231 orthotopic xenograft model. We will use large sample sizes to monitor for survival and tumor regression benefits, and also to monitor reovirus s1 cleavage and virus replication kinetics within the tumors. If BC MPs reproducibly restrict reovirus oncolysis, then BC MP-resistant reovirus will show higher tumor clearance and infectious virus relative to ReoWT in multiple BC models, and prove itself worthwhile of clinical testing. Aim 2. We observed reovirus-inactivation and s1-cleavage by extracellular extracts of three mouse BC tumor types and five BC human cell lines. Triple negative breast cancers (TNBCs) are hardest to treat, so in aim 2, we will establish the repertoire of TNBC models that inactivate reovirus through MPs in their microenvironment. Secretion of MPs will first be evaluated in 17 human TNBC cell lines, and then confirmed in mouse xenograft tumors for 3 of these models. We will also evaluate reovirus-inactivating MP levels in the E0771 and EMT6 syngeneic orthotopic mouse TNBC models. The findings will not only reveal the prevalence of MPs as barriers to reovirus oncolysis, but will enable future efficacy trials in a variation of aggressive, metastatic TNBC models with different mouse genetic backgrounds and tumor immunities. Aim 3 will create reovirus variants with highly divergent s1 proteins that resist BC MPs, retain utmost infectivity in breast cancer cells, and avoid antibody cross-neutralization. The T249I mutation in s1 brought benefits to oncolytic activity but also costs to virus fitness that if overcome, may further enhance oncolytic activity. We therefore plan to switch s1 of ReoWT with s1 proteins from diverse reoviruses with as little as 22% amino acid similarity and that can withstand proteolytic cleavage. Some of these recombinant viruses that withstand cleavage will also ideally retain high infectivity in BC cells. Moreover, s1 is the immunodominant protein during antibody neutralization. By replacing s1 of ReoWT with s1 from other reovirus serotypes that do not cross-neutralize, we will create antigenically-distinct versions of oncolytic reovirus. In future, these recombinants will create the first tools to test the extent of oncolytic impairment imposed by host neutralizing antibodies against subsequent injections of the same oncolytic virus. OVERALL SIGNIFICANCE: This proposed project will provide detailed understanding of the obstacle created by BC MPs to reovirus therapy of breast cancers, and best-strategies to overcome this obstacle to maximize therapeutic efficacy. Note that other oncolytic viruses, antibodies, and protein-based therapies are proteinaceous as well and could be vulnerable to proteolysis; our novel findings on proteolysis as an obstacle to therapeutic activity in BC might therefore extend to other proteinaceous therapies as well.
Competitiondate
202103
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Shmulevitz, Maya
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~